Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Shanghai YingLi Pharmaceutical Co. Ltd.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
histologically or cytologically confirmed relapse and/or refractory B cell hematologic malignancies(Excluding follicular lymphoma)
prior treatment with ≥1 prior standard anti-tumor regimens and 2 courses of treatments at least
eastern cooperative oncology group performance status of 0 to 2
life expectancy of at least 3 months
presence of \>1.5cm radiographically measurable lymphadenopathy or extranodal lymphoid malignancy, and legibility in two vertical directions
acceptable organ functions
discontinuation of all other antitumor therapies before the first drug dose administration
for men and women of childbearing potential, willingness to abstain from sexual intercourse or employ an effective method of contraception during the study drug administration and follow-up six periods
willingness and ability to provide written informed consent and to comply with the protocol requirements
You may not be if
prior therapy with PI3K-delta inhibitors(except the intolerable subjects)
the dosage of steroid hormone(predisone equivalent) was greater than 20mg/d, and lasted for more than 14 days
medical condition of difficulty in swallowing, malabsorption, or other chronic gastrointestinal disease, or conditional that may hamper compliance and/or absorption of the investigational product
concurrent drugs which maybe prolong the QT during the study period
subjects with central nervous system metastasis
Prior or current medical condition of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severe impairment of lung function, etc
active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
known history of chronic active hepatitis B infection, chronic active hepatitis C
known history of immunodeficiency, including HIV positive test, other acquired or congenital immunodeficiency disorders, organ transplantation or allogeneic bone marrow transplantation
autologous hematopoietic stem cell transplantation was received within 90 days before the first dose administration
pregnancy or breastfeeding
prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the participant or impair the assessment of study results
receiving granulocyte colony-stimulating factor(GCSF) or blood transfusion within seven days before screening
history of a non-lymphoma malignancy except for adequately treated local basal cell carcinoma of the skin and cervical carcinoma in situ
subjects, in the opinion of the the Investigator, who are unsuitable to participate in the study for any other reason.